Exagen Inc. E08A.F Stock
Exagen Inc. Price Chart
Exagen Inc. E08A.F Financial and Trading Overview
Exagen Inc. stock price | 1.36 EUR |
Previous Close | 2.78 EUR |
Open | 2.9 EUR |
Bid | 2.9 EUR x N/A |
Ask | 2.98 EUR x N/A |
Day's Range | 2.9 - 2.9 EUR |
52 Week Range | 2 - 8.4 EUR |
Volume | 2.25K EUR |
Avg. Volume | 40 EUR |
Market Cap | 50.71M EUR |
Beta (5Y Monthly) | 1.246535 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.25 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 25 EUR |
E08A.F Valuation Measures
Enterprise Value | 28.86M EUR |
Trailing P/E | N/A |
Forward P/E | -1.60221 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.0930048 |
Price/Book (mrq) | 1.357678 |
Enterprise Value/Revenue | 0.622 |
Enterprise Value/EBITDA | -0.785 |
Trading Information
Exagen Inc. Stock Price History
Beta (5Y Monthly) | 1.246535 |
52-Week Change | -46.13% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.4 EUR |
52 Week Low | 2 EUR |
50-Day Moving Average | 2.5 EUR |
200-Day Moving Average | 2.7 EUR |
E08A.F Share Statistics
Avg. Volume (3 month) | 40 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 16.83M |
Float | 6.44M |
Short Ratio | N/A |
% Held by Insiders | 27.37% |
% Held by Institutions | 61.34% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -96.55% |
Operating Margin (ttm) | -83.13% |
Gross Margin | 47.57% |
EBITDA Margin | -79.19% |
Management Effectiveness
Return on Assets (ttm) | -23.95% |
Return on Equity (ttm) | -79.93% |
Income Statement
Revenue (ttm) | 46.4M EUR |
Revenue Per Share (ttm) | 2.7 EUR |
Quarterly Revenue Growth (yoy) | 8.00% |
Gross Profit (ttm) | 21.35M EUR |
EBITDA | -36745000 EUR |
Net Income Avi to Common (ttm) | -44803000 EUR |
Diluted EPS (ttm) | -2.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 52.18M EUR |
Total Cash Per Share (mrq) | 3.1 EUR |
Total Debt (mrq) | 35.28M EUR |
Total Debt/Equity (mrq) | 98.17 EUR |
Current Ratio (mrq) | 7.091 |
Book Value Per Share (mrq) | 2.136 |
Cash Flow Statement
Operating Cash Flow (ttm) | -33319000 EUR |
Levered Free Cash Flow (ttm) | -25681500 EUR |
Profile of Exagen Inc.
Country | Germany |
State | CA |
City | Vista |
Address | 1261 Liberty Way |
ZIP | 92081 |
Phone | 760 560 1501 |
Website | https://www.exagen.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 199 |
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Q&A For Exagen Inc. Stock
What is a current E08A.F stock price?
Exagen Inc. E08A.F stock price today per share is 1.36 EUR.
How to purchase Exagen Inc. stock?
You can buy E08A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Exagen Inc.?
The stock symbol or ticker of Exagen Inc. is E08A.F.
Which industry does the Exagen Inc. company belong to?
The Exagen Inc. industry is Diagnostics & Research.
How many shares does Exagen Inc. have in circulation?
The max supply of Exagen Inc. shares is 17.49M.
What is Exagen Inc. Price to Earnings Ratio (PE Ratio)?
Exagen Inc. PE Ratio is now.
What was Exagen Inc. earnings per share over the trailing 12 months (TTM)?
Exagen Inc. EPS is -1.25 EUR over the trailing 12 months.
Which sector does the Exagen Inc. company belong to?
The Exagen Inc. sector is Healthcare.